|本期目录/Table of Contents|

[1]中华医学会感染病学分会.终末期肝病合并感染诊治专家共识[J].传染病信息,2018,04:289-300330.
 Chinese Society of Infectious Disease,Chinese Medical Association.Expert consensus on diagnosis and treatment of end-stage liver disease complicated with infections[J].Infectious Disease Information,2018,04:289-300330.
点击复制

终末期肝病合并感染诊治专家共识(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2018年04期
页码:
289-300330
栏目:
特别报道
出版日期:
2018-08-30

文章信息/Info

Title:
Expert consensus on diagnosis and treatment of end-stage liver disease complicated with infections
作者:
中华医学会感染病学分会
中华医学会感染病学分会
Author(s):
Chinese Society of Infectious Disease Chinese Medical Association
关键词:
终末期肝病感染诊断治疗共识
Keywords:
End stage of liver disease Infection Diagnosis Therapy Consensus
分类号:
R575;R44;R45
DOI:
10.3969/j.issn.1007-8134.2018.04.001
文献标识码:
A
摘要:
终末期肝病(end-stage liver disease, ESLD)发生发展中,感染可以诱发或加重ESLD 肝功能失代偿的发生,亦是 ESLD 发展过程中最易出现的并发症之一。ESLD 合并感染的规范诊疗需求迫切,国内外尚无针对 ESLD 合并感染性疾病的诊治指南、行业标准或专家共识,本共识旨在指导并提高临床医务工作者对 ESLD 合并感染疾病的综合诊治能力。
Abstract:
End-stage liver disease (ESLD) is a life threaten clinical syndrome with significantly increasing mortality when the patients complicated with infections. For patients with ESLD, infections can induce or aggravate the occurrence of liver decompensation. In turn infections are among the most common complications under disease progression. There is lacking of working procedures for early diagnosis and appropriate management for patients of ESLD complicated with infections, neither guidelines nor consenus at home and abroad. This consensus assembles up-to-date knowledge and experience across Chinese colleagues and provides principles as well as working procedures for clinicians to diagnose and treat an ESLD patient complicated with infections.

参考文献/References


[1] Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J]. Hepatology, 2000, 31(4): 864-871. doi: 10.1053/he.2000.5852.
[2] Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers[J]. Gastroenterology, 2003, 124(1): 91-96. doi: 10.1053/gast.2003.50016.
[3] Wang X, Sarin SK, Ning Q. Definition of ACLF and inclusion criteria for extra-hepatic organ failure[J]. Hepatol Int, 2015, 9(3): 360-365. doi: 10.1007/s12072-015-9637-x.
[4] 陈韬,宁琴 . 终末期肝病合并感染诊治的热点与难点[J]. 中华临床感染病杂志,2017,10(5): 389-393. doi: 10.3760/cma. j.issn.1674-2397.2017.05.014. Tao Chen, Qin Ning. Highlights of diagnosis and treatment for end stage of liver disease with infection[J]. Chin J Clin Infect Dis, 2017, 10(5): 389-393. doi: 10.3760/cma.j.issn.1674-2397.2017.05.014.
[5] Arvaniti V, D’Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J]. Gastroenterology, 2010, 139(4): 1246-1256, 1256 e1241-1245. doi: 10.1053/j.gastro.2010.06.019.
[6] Jha AK, Nijhawan S, Suchismita A. Sepsis in acute on chronic liver failure[J]. Dig Dis Sci, 2011, 56(4): 1245-1246; author reply 1246. doi: 10.1007/s10620-011-1605-2.
[7] Yang L, Wu T, Li J. Bacterial Infections in Acute-on-Chronic Liver Failure[J]. Semin Liver Dis, 2018, 38(2): 121-133. doi: 10.1055/s-0038-1657751.
[8] EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018. doi: 10.1016/ j.jhep.2018.03.024.
[9] Oey RC, de Man RA, Erler NS, et al. Microbiology and antibiotic susceptibility patterns in spontaneous bacterial peritonitis: A study of two Dutch cohorts at a 10-year interval[J]. United European Gastroenterol J, 2018, 6(4): 614-621. doi: 10.1177/2050640617744456.
[10] Ning NZ, Li T, Zhang JL, et al. Clinical and bacteriological features and prognosis of ascitic fluid infection in Chinese patients with cirrhosis[J]. BMC Infect Dis, 2018, 18(1): 253. doi: 10.1186/ s12879-018-3101-1.
[11] Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013[J]. J Hepatol, 2014, 60(6): 1310-1324. doi: 10.1016/j.jhep.2014.01.024.
[12] Kurup A, Liau KH, Ren J, et al. Antibiotic management of complicated intra-abdominal infections in adults: The Asian perspective[J]. Ann Med Surg (Lond), 2014, 3(3): 85-91. doi: 10.1016/j.amsu.2014.06.005.
[13] Sofjan AK, Musgrove RJ, Beyda ND, et al. Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxoneresistant organisms at a large tertiary center in the United State[s J]. J Glob Antimicrob Resist, 2018. doi: 10.1016/j.jgar.2018.05.015.
[14] Salerno F, Borzio M, Pedicino C, et al. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study[J]. Liver Int, 2017, 37(1): 71-79. doi: 10.1111/liv.13195.
[15] Sarin SK, Choudhury A. Acute-on-chronic liver failure: terminology, mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(3): 131-149. doi: 10.1038/ nrgastro.2015.219.
[16] Marsden PA, Ning Q, Fung LS, et al. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis[J]. J Clin Invest, 2003, 112(1): 58-66. doi: 10.1172/JCI18114.
[17] Wu Z, Han M, Chen T, et al. Acute liver failure: mechanisms of immune-mediated liver injury[J]. Liver Int, 2010, 30(6): 782- 794. doi: 10.1111/j.1478-3231.2010.02262.x.
[18] Wang X, Ning Q. Immune mediated liver failure[J]. EXCLI J, 2014, 13: 1131-1144.
[19] Wiest R, Krag A, Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond[J]. Gut, 2012, 61(2): 297-310. doi: 10.1136/gutjnl-2011-300779.
[20] MacIntosh T. Emergency Management of Spontaneous Bacterial Peritonitis - A Clinical Review[J]. Cureus, 2018, 10(3): e2253. doi: 10.7759/cureus.2253.
[21] Hwang SY, Yu SJ, Lee JH, et al. Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis [J]. Eur J Clin Microbiol Infect Dis, 2014, 33(2): 259-264. doi: 10.1007/s10096-013-1953-2.
[22] Lahmer T, Brandl A, Rasch S, et al. Fungal Peritonitis: Underestimated Disease in Critically Ill Patients with Liver Cirrhosis and Spontaneous Peritonitis[J]. PLoS One, 2016, 11(7): e0158389. doi: 10.1371/journal.pone.0158389.
[23] Vaid U, Kane GC. Tuberculous Peritonitis[J]. Microbiol Spectr, 2017, 5(1). doi: 10.1128/microbiolspec.TNMI7-0006-2016.
[24] Vaz AM, Peixe B, Ornelas R, et al. Peritoneal tuberculosis as a cause of ascites in a patient with cirrhosis[J]. BMJ Case Rep, 2017, 2017. doi: 10.1136/bcr-2017-220500.
[25] Huang HJ, Yang J, Huang YC, et al. Diagnostic feature of tuberculous peritonitis in patients with cirrhosis: A matched casecontrol study[J]. Exp Ther Med, 2014, 7(4): 1028-1032. doi: 10.3892/etm.2014.1538.
[26] Shalimar, Rout G, Jadaun SS, et al. Prevalence, predictors and patients[J]. Dig Liver Dis, 2018. doi: 10.1016/j.dld.2018.05.013.
[27] El-Amin H, Sabry AMM, Ahmed RE, et al. Types and microbiological spectrum of infections in patients with cirrhosis: A single-centre experience in Upper Egypt[J]. Arab J Gastroenterol, 2017, 18(3): 159-164. doi: 10.1016/j.ajg.2017.09.005.
[28] Cai J, Zhang M, Han T, et al. Characteristics of infection and its impact on short-term outcome in patients with acute-on-chronic liver failure[J]. Medicine (Baltimore), 2017, 96(37): e8057. doi: 10.1097/MD.0000000000008057.
[29] Park JW, Lee JK, Lee KT, et al. How to interpret the bile culture results of patients with biliary tract infections[J]. Clin Res Hepatol Gastroenterol, 2014, 38(3): 300-309. doi: 10.1016/ j.clinre.2014.02.005.
[30] Mucke MM, Kessel J, Mucke VT, et al. The role of Enterococcus spp. and multidrug-resistant bacteria causing pyogenic liver abscesses[J]. BMC Infect Dis, 2017, 17(1): 450. doi: 10.1186/ s12879-017-2543-1.
[31] Gomez-Hurtado I, Such J, Sanz Y, et al. Gut microbiota-related complications in cirrhosis[J]. World J Gastroenterol, 2014, 20(42): 15624-15631. doi: 10.3748/wjg.v20.i42.15624.
[32] Giannelli V, Di Gregorio V, Iebba V, et al. Microbiota and the gutliver axis: bacterial translocation, inflammation and infection in cirrhosis[J]. World J Gastroenterol, 2014, 20(45): 16795-16810. doi: 10.3748/wjg.v20.i45.16795.
[33] Navasa M, Rodes J. Bacterial infections in cirrhosis[J]. Liver Int, 2004, 24(4): 277-280. doi: 10.1111/j.1478-3231.2004.0934.x.
[34] Bartoletti M, Giannella M, Caraceni P, et al. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis[J]. J Hepatol, 2014, 61(1): 51-58. doi: 10.1016/j.jhep.2014.03.021.
[35] Zhao H, Gu X, Zhao R, et al. Evaluation of prognostic scoring systems in liver cirrhosis patients with bloodstream infection [J]. Medicine (Baltimore), 2017, 96(50): e8844. doi: 10.1097/ MD.0000000000008844.
[36] Xie Y, Tu B, Zhang X, et al. Investigation on outcomes and bacterial distributions of liver cirrhosis patients with gram-negative bacterial bloodstream infection[J]. Oncotarget, 2018, 9(3): 3980-3995. doi: 10.18632/oncotarget.23582.
[37] Xie Y, Tu B, Xu Z, et al. Bacterial distributions and prognosis of bloodstream infections in patients with liver cirrhosis[J]. Sci Rep, 2017, 7(1): 11482. doi: 10.1038/s41598-017- 11587-1.
[38] Liu BM, Chung KJ, Chen CH, et al. Risk factors for the outcome of cirrhotic patients with soft tissue infections[J]. J Clin Gastroenterol, 2008, 42(3): 312-316. doi: 10.1097/ MCG.0b013e31802dbde8.
[39] Su CM, Chang WN, Tsai NW, et al. Clinical features and outcome of community-acquired bacterial meningitis in adult patients with liver cirrhosis[J]. Am J Med Sci, 2010, 340(6): 452-456. doi: 10.1097/MAJ.0b013e3181ee988d.
[40] Barahona-Garrido J, Hernandez-Calleros J, Tellez-Avila FI, et al. Bacterial meningitis in cirrhotic patients: case series and description of the prognostic role of acute renal failure[J]. J Clin Gastroenterol, 2010, 44(9): e218-223. doi: 10.1097/ MCG.0b013e3181d88d53.
[41] Pagliano P, Boccia G, De Caro F, et al. Bacterial meningitis complicating the course of liver cirrhosis[J]. Infection, 2017, 45(6): 795-800. doi: 10.1007/s15010-017-1039-7.
[42] Epstein O, Dick R, Sherlock S. Prospective study of periostitis and finger clubbing in primary biliary cirrhosis and other forms of chronic liver disease[J]. Gut, 1981, 22(3): 203-206.
[43] Allaire M, Cadranel JD, Bureau C, et al. Severe liver failure rather than cirrhosis is associated with mortality in patients with infectious endocarditis: a retrospective case-control study [J]. Eur J Gastroenterol Hepatol, 2018. doi: 10.1097/ MEG.0000000000001155.
[44] Ruiz-Morales J, Ivanova-Georgieva R, Fernandez-Hidalgo N, et al. Leftsided infective endocarditis in patients with liver cirrhosis[J]. J Infect, 2015, 71(6): 627-641. doi: 10.1016/j.jinf.2015.09.005.
[45] Lee S, Um T, Joe SG, et al. Changes in the clinical features and prognostic factors of endogenous endophthalmitis: fifteen years of clinical experience in Korea[J]. Retina, 2012, 32(5): 977-984. doi: 10.1097/IAE.0b013e318228e312.
[46] Chung KS, Kim YK, Song YG, et al. Clinical review of endogenous endophthalmitis in Korea: a 14-year review of culture positive cases of two large hospitals[J]. Yonsei Med J, 2011, 52(4): 630- 634. doi: 10.3349/ymj.2011.52.4.630.
[47] Gustot T, Durand F, Lebrec D, et al. Severe sepsis in cirrhosis[J]. Hepatology, 2009, 50(6): 2022-2033. doi: 10.1002/hep.23264.
[48] Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013, 144(7): 1426-1437, 1437 e1421-1429. doi: 10.1053/j.gastro.2013.02.042.
[49] Fernandez J, Gustot T. Management of bacterial infections in cirrhosis[J]. J Hepatol, 2012, 56 Suppl 1: S1-12. doi: 10.1016/ S0168-8278(12)60002-6.
[50] Mueller C, Compher C, Ellen DM. A.S.P.E.N. clinical guidelines: Nutrition screening, assessment, and intervention in adults [J]. JPEN J Parenter Enteral Nutr, 2011, 35(1): 16-24. doi: 10.1177/0148607110389335.
[51] 詹斯·康卓普,雷米·梅耶. 营养风险筛查 NRS 2002 改善临床结局[J]. 中华临床营养杂志. 2013, 21(3): 133-139. doi: 10.3760/cma.j.issn.1674- 635X.2013.03.001. Jens Kondrup, Remy Meier. Screening by NRS 2002 improves clinical outcome[J]. Chinese Journal of Clinical Nutrition.2013,21(3):133-139. doi: 10.3760/cma.j.issn.1674- 635X.2013.03.001.
[52] Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2012, 10(2): 166-173, 173 e161. doi: 10.1016/j.cgh.2011.08.028.
[53] Holt EW, Frederick RT, Verhille MS. Prognostic value of muscle wasting in cirrhotic patients[J]. Clin Gastroenterol Hepatol, 2012, 10(9): 1056; author reply 1056-1057. doi: 10.1016/ j.cgh.2012.03.019. [54] Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition[J].Clin Nutr, 2017, 36(1): 49-64. doi: 10.1016/j.clnu.2016.09.004.
[55] Cabre E, Rodriguez-Iglesias P, Caballeria J, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial[J]. Hepatology, 2000, 32(1): 36-42. doi: 10.1053/jhep.2000.8627.
[56] Plauth M, Cabre E, Campillo B, et al. ESPEN Guidelines on Parenteral Nutrition: hepatology[J]. Clin Nutr, 2009, 28(4): 436- 444. doi: 10.1016/j.clnu.2009.04.019.
[57] Plank LD, Gane EJ, Peng S, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial[J]. Hepatology, 2008, 48(2): 557-566. doi: 10.1002/hep.22367.
[58] Nakaya Y, Okita K, Suzuki K, et al. BCAA-enriched snack improves nutritional state of cirrhosis[J]. Nutrition, 2007, 23(2): 113-120. doi: 10.1016/j.nut.2006.10.008.
[59] Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis[J]. Clin Gastroenterol Hepatol, 2005, 3(7): 705-713.
[60] Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial[J]. Gastroenterology, 2003, 124(7): 1792-1801.
 [61] Sun X, Duan X, Wang C, et al. Protective effects of glycyrrhizic acid against non-alcoholic fatty liver disease in mice[J]. Eur J

[62] Polyak SJ, Ferenci P, Pawlotsky JM. Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection[J]. Hepatology, 2013, 57(3): 1262-1271. doi: 10.1002/hep.26179.

[63] Federico A, Dallio M, Loguercio C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years[J]. Molecules, 2017, 22(2). doi: 10.3390/molecules22020191.
[64] 中华医学会感染病学分会,肝脏炎症及其防治专家共识专家委员会. 肝脏炎症及其防治专家共识[J]. 中华传染病杂志. 2014, 32 (2):65-75. doi:10.3760/cma.j.issn.1000-6680.2014.02.001. Chinese Society of Infectious Diseases,Chinese Medical Association. Expert consensus on liver inflammation and its prevention and treatment[J]. Chin J Intect Dis, 2014, 23(2): 65- 75. doi: 10.3760/cma.j.issn.1000-6680.2014.02.001.
[65] Sola E, Sole C, Gines P. Management of uninfected and infected ascites in cirrhosis[J]. Liver Int, 2016, 36 Suppl 1: 109-115. doi: 10.1111/liv.13015.
[66] Pericleous M, Sarnowski A, Moore A, et al. The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations[J]. Eur J Gastroenterol Hepatol, 2016, 28(3): e10-18. doi: 10.1097/MEG.0000000000000548.
[67] Camerini R, Garaci E. Historical review of thymosin alpha 1 in infectious diseases[J]. Expert Opin Biol Ther, 2015, 15 Suppl 1: S117-127. doi: 10.1517/14712598.2015.1033393.
[68] Li C, Bo L, Liu Q, et al. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis[J]. Int J Infect Dis, 2015, 33: 90-96. doi: 10.1016/j.ijid.2014.12.032.
[69] Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial[J]. Crit Care, 2013, 17(1):R8. doi: 10.1186/ cc11932.
[70] Xu D, Zhao M, Song Y, et al. Novel insights in preventing Gramnegative bacterial infection in cirrhotic patients: review on the effects of GM-CSF in maintaining homeostasis of the immune system[J]. Hepatol Int, 2015, 9(1): 28-34. doi: 10.1007/s12072- 014-9588-7.
[71] Shiomi A, Usui T, Ishikawa Y, et al. GM-CSF but not IL-17 iscritical for the development of severe interstitial lung disease inSKG mice[J]. J Immunol, 2014, 193(2): 849-859. doi: 10.4049/jimmunol.1303255.
[72] Kedarisetty CK, Anand L, Bhardwaj A, et al. Combination ofgranulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis[J].Gastroenterology, 2015, 148(7): 13
[73] Chanson P, Pariente A. [Combination of granulocyte colonystimulating factor and erythropoietin in decompensated cirrhosis: a positive essay?][J]. Rev Prat, 2015, 65(4): 472-473.
[74] Shouval D. The pros and cons of lamivudine vs. entecavir in decompensated or severe acute exacerbation of chronic hepatitis B[J]. J Hepatol, 2014, 60(6): 1108-1109. doi: 10.1016/ j.jhep.2014.03.004.
[75] Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016, 63(1): 261-283. doi: 10.1002/hep.28156.
[76] Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J].Hepatology, 2015, 62(3): 932-954. doi: 10.1002/hep.27950.
[77] O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease [J]. Am J Gastroenterol, 2010, 105(1): 14-32; quiz 33. doi: 10.1038/ajg.2009.593.
[78] Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012[J]. Hepatology, 2013, 57(4): 1651-1653. doi: 10.1002/hep.26359.
[79] EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J]. J Hepatol, 2010, 53(3): 397-417. doi: 10.1016/ j.jhep.2010.05.004.
[80] Nanchal RS, Ahmad S. Infections in Liver Disease[J]. Crit Care Clin, 2016, 32(3): 411- 424. doi: 10.1016/j.ccc.2016.03.006.
[81] Shi L, Wu D, Wei L, et al. Nosocomial and Community-Acquired Spontaneous Bacterial Peritonitis in patients with liver cirrhosis in China: Comparative Microbiology and Therapeutic Implications[J]. Sci Rep, 2017, 7: 46025. doi: 10.1038/srep46025.
[82] Quan J, Zhao D, Liu L, et al. High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China[J]. J Antimicrob Chemother, 2017, 72(1): 273-280. doi: 10.1093/jac/dkw372.
[83] Dever JB, Sheikh MY. Review article: spontaneous bacterial peritonitis--bacteriology, diagnosis, treatment, risk factors and prevention[J]. Aliment Pharmacol Ther, 2015, 41(11): 1116- 1131. doi: 10.1111/apt.13172.
[84] Fiore M, Leone S. Spontaneous fungal peritonitis: Epidemiology, current evidence and future prospective[J]. World J Gastroenterol, 2016, 22(34): 7742-7747. doi: 10.3748/wjg.v22. i34.7742.
[85] Hassan EA, Abd El-Rehim AS, Hassany SM, et al. Fungal
infection in patients with end-stage liver disease: low frequency or low index of suspicion[J]. Int J Infect Dis, 2014, 23: 69-74. doi: 10.1016/j.ijid.2013.12.014.
[86] Fiore M, Andreana L, Leone S. Preemptive therapy of spontaneous fungal peritonitis[J]. Hepatology, 2016, 64(3): 997-998. doi: 10.1002/hep.28448.
[87] Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis[J]. Am J Respir Crit Care Med, 2003, 167(4): 603-662. doi: 10.1164/ rccm.167.4.603.
[88] Sanai FM, Bzeizi KI. Systematic review: tuberculous peritonitis- -presenting features, diagnostic strategies and treatment[J]. Aliment Pharmacol Ther, 2005, 22(8): 685-700. doi: 10.1111/ j.1365-2036.2005.02645.x.
[89] Saigal S, Agarwal SR, Nandeesh HP, et al. Safety of an ofloxacinbased antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report [J]. J Gastroenterol Hepatol, 2001, 16(9): 1028-1032.
[90] Sartelli M, Viale P, Catena F, et al. 2013 WSES guidelines for management of intra-abdominal infections[J]. World J Emerg Surg, 2013, 8(1): 3. doi: 10.1186/1749-7922-8-3.
[91] Aguado JM, Silva JT, Fernandez-Ruiz M, et al. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA- SEIMC/REIPI recommendations[J]. Transplant Rev (Orlando), 2018, 32(1): 36-57. doi: 10.1016/j.trre.2017.07.001.
[92] Govindan S, Hyzy RC. The 2016 Guidelines for Hospital-acquired and Ventilator-associated Pneumonia. A Selection Correction?[J]. Am J Respir Crit Care Med, 2016, 194(6): 658-660. doi: 10.1164/ rccm.201607-1447ED.
[93] Chen J, Yang Q, Huang J, et al. Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study[J]. Int J Med Sci, 2013, 10(12): 1625-1631. doi: 10.7150/ijms.6824.
[94] 张国强,姚艺辉,许奇萍,等. 胆道感染微生物分布及菌
株耐药性分析[J]. 实验与检验医学,2008(05):551-552.
10.3969/j.issn.1674-1129.2008.05.039. Guoqiang Zhang, Yihui Yao, Qiping Xu, et al. Analysis of microbial distribution and drug resistance of biliary tract infection[J]. Laboratory and laboratory medicine. 2008(05):551-552.10.3969/[95] 郝成飞,孙兰菊,李忠廉. 胆道感染病原菌对抗菌药物的敏 感性分析研究[J]. 中华医院感染学杂志,2011(01):128- 130. Chengfei Hao, Lanju Sun, Zhonglian Li. Pathogens causing biliary tract infection and their sensitivity to antibiotics[J]. Chinese Journal of Hospital Infectious Diseases. 2011(01):128-130.
[96] Fuks D, Cosse C, Regimbeau JM. Antibiotic therapy in acute calculous cholecystitis[J]. J Visc Surg, 2013, 150(1): 3-8. doi: 10.1016/j.jviscsurg.2013.01.004.
[97] de Santibanes M, Glinka J, Pelegrini P, et al. Extended antibiotic therapy versus placebo after laparoscopic cholecystectomy for mild and moderate acute calculous cholecystitis: A randomized double-blind clinical trial[J]. Surgery, 2018. doi: 10.1016/ j.surg.2018.01.014.
[98] Ansaloni L, Pisano M, Coccolini F, et al. 2016 WSES guidelines on acute calculous cholecystitis[J]. World J Emerg Surg, 2016, 11: 25. doi: 10.1186/s13017-016-0082-5.
[99] Mouloudi E, Massa E, Piperidou M, et al. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study [J]. Transplant Proc, 2014, 46(9): 3219-3221. doi: 10.1016/ j.transproceed.2014.09.160.
[100] Barreto R, Elia C, Sola E, et al. Urinary neutrophil gelatinaseassociated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections[J]. J Hepatol, 2014, 61(1): 35-42. doi: 10.1016/j.jhep.2014.02.023.
[101] Bajaj JS, O’Leary JG, Reddy KR, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience[J]. Hepatology, 2012, 56(6): 2328-2335. doi: 10.1002/hep.25947.
[102] Toshikuni N, Ujike K, Yanagawa T, et al. Candida albicans endophthalmitis after extracorporeal shock wave lithotripsy in a patient with liver cirrhosis[J]. Intern Med, 2006, 45(22): 1327- 1332.
[103] Zhao SJ, Fu YQ, Zhu MX, et al. [Patients of Escherichia coli bloodstream infection: analysis of antibiotic resistance and predictors of mortality][J]. Zhonghua Yi Xue Za Zhi, 2017, 97(32): 2496- 2500. doi:10.3760/cma.j.issn.0376-2491.2017.32.005.
[104] Nelson AN, Justo JA, Bookstaver PB, et al. Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections[J]. Infection, 2017, 45(5): 613-620. doi: 10.1007/s15010-017-1020-5.
[105] Piotrowski D, Boron-Kaczmarska A. Bacterial infections and hepatic encephalopathy in liver cirrhosis-prophylaxis and treatment[J]. Adv Med Sci, 2017, 62(2): 345-356. doi: 10.1016/ j.advms.2016.11.009.
[106] Huang KC, Tsai YH, Lee MS. Model for end-stage liver disease (MELD) score as a predictor and monitor of mortality in patients with Vibrio vulnificus necrotizing skin and soft tissue infection[s J]. PLoS Negl Trop Dis, 2015, 9(4): e0003720. doi: 10.1371/journal. pntd.0003720.
[107] 何礼贤,肖永红,陆权,等. 国家抗微生物治疗指南. 人民卫 生出版社,2012 年 12 月, 北京. Lixian He, Yonghong Xiao, Quan Lu, et al. National Antimicrobial Treatment Guidelines. People’s Health Publishing House, 2012, Oct. Beijing.
[108] Wu HS, Wang FD, Tseng CP, et al. Characteristics of healthcareassociated and community-acquired Klebsiella pneumoniae bacteremia in Taiwan[J]. J Infect, 2012, 64(2): 162-168. doi: 10.1016/j.jinf.2011.11.005.
[109] Doron SI, Hibberd PL, Gorbach SL. Probiotics for prevention of antibiotic-associated diarrhea[J]. J Clin Gastroenterol, 2008, 42 Suppl 2: S58-63. doi: 10.1097/MCG.0b013e3181618ab7.
[110] Khediri F, Mrad AI, Azzouz M, et al. Efficacy of diosmectite (smecta) in the treatment of acute watery diarrhoea in adults: a multicentre, randomized, double-blind, placebo- controlled, parallel group study[J]. Gastroenterol Res Pract, 2011, 2011: 783196. doi: 10.1155/2011/783196.
[111] Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections [J]. Am J Gastroenterol, 2013, 108(4): 478- 498; quiz 499. doi: 10.1038/ajg.2013.4.
[112] Moore JE, Barton MD, Blair IS, et al. The epidemiology of antibiotic resistance in Campylobacter[J]. Microbes Infect, 2006, 8(7): 1955-1966. doi: 10.1016/j.micinf.2005.12.030.
[113] Negri M, Silva S, Henriques M, et al. Insights into Candida tropicalis nosocomial infections and virulence factors[J]. Eur J Clin Microbiol Infect Dis, 2012, 31(7): 1399- 1412. doi: 10.1007/ s10096-011-1455-z.
[114] Pena MA, Horga JF, Zapater P. Variations of pharmacokinetics of drugs in patients with cirrhosis[J]]. Expert Rev Clin Pharmacol, 2016, 9(3): 441-458. doi: 10.1586/17512433.2016.1135733.
[115] Halilovic J, Heintz BH. Antibiotic dosing in cirrhosis[J]. Am J Health Syst Pharm, 2014, 71(19): 1621-1634. doi: 10.2146/ ajhp140031.
[116] Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care[J]. J Antimicrob Chemother, 2011, 66(7): 1431- 1446. doi: 10.1093/jac/dkr159.
[117] Lan P, Wang SJ, Shi QC, et al. Comparison of the predictive value of scoring systems on the prognosis of cirrhotic patients with suspected infection[J]. Medicine (Baltimore), 2018, 97(28): e11421. doi: 10.1097/MD.0000000000011421.
[118] Wong-Beringer A, Kriengkauykiat J. Systemic antifungal therapy: new options, new challenges[J]. Pharmacotherapy, 2003, 23(11): 1441-1462.
[119] ChangY, BurckartGJ, LeskoLJ, et al. Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels[J]. J Clin Pharmacol, 2013, 53(9): 962-966. doi: 10.1002/jcph.128.
[120] Chen Y, Ji F, Guo J, et al. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology[J]. Sci Rep, 2016, 6: 34055. doi: 10.1038/srep34055.
[121] Ling Z, Liu X, Cheng Y,et al. Blood microbiota as a potential noninvasive diagnostic biomarker for liver fibrosis in severely obese patients: Choose carefully[J]. Hepatology, 2017, 65(5): 1775- 1776. doi: 10.1002/hep.28987.
[122] Pande C, Kumar A, Sarin SK. Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomizedcontrolled trial[J]. Eur J Gastroenterol Hepatol, 2012, 24(7): 831-839. doi: 10.1097/MEG.0b013e3283537d61.
[123] Cordoba J, Ventura-Cots M, Simon-Talero M, et al. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF)[J]. J Hepatol, 2014, 60(2): 275-281. doi: 10.1016/j.jhep.2013.10.004.
[124] Victor DW, 3rd, Quigley EM. Microbial therapy in liver disease: probiotics probe the microbiome-gut-liver-brain axis[J]. Gastroenterology, 2014, 147(6): 1216-1218. doi: 10.1053/
j.gastro.2014.10.023.
[125] Zhou F, Peng Z, Murugan R, et al. Blood purification and mortality in sepsis: a meta-analysis of randomized trials[J]. Crit Care Med, 2013, 41(9): 2209-2220. doi: 10.1097/CCM.0b013e31828cf412.
[126] Rimmele T, Kellum JA. Clinical review: blood purification for sepsis[J]. Crit Care, 2011, 15(1): 205. doi: 10.1186/cc9411.
[127] Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis[J]. Artif Organs, 2003, 27(9): 792- 801.
[128] Mookerjee RP. Prognosis and Biomarkers in Acute-on-Chronic Liver Failure[J]. Semin Liver Dis, 2016, 36(2): 127-132. doi: 10.1055/s-0036-1583200.
[129] Reddy SS, Civan JM. From Child-Pugh to Model for End-Stage Liver Disease: Deciding Who Needs a Liver Transplant[J]. Med Clin North Am, 2016, 100(3): 449-464. doi: 10.1016/ j.mcna.2015.12.002.
[130] Nemes B, Gaman G, Polak WG, et al. Extended-criteria donors in liver transplantation Part II: reviewing the impact of extendedcriteria donors on the complications and outcomes of liver transplantation[J]. Expert Rev Gastroenterol Hepatol, 2016, 10(7): 841-859. doi: 10.1586/17474124.2016.1149062.
[131] Ou P, Chen Y, Li B, et al. Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital[J]. Springerplus, 2015, 4: 802. doi: 10.1186/s40064-015-1600-8.
[132] McPhail MJ, Farne H, Senvar N, et al. Ability of King’s College Criteria and Model for End-Stage Liver Disease Scores to Predict Mortality of Patients With Acute Liver Failure: A Meta-analysis [J]. Clin Gastroenterol Hepatol, 2016, 14(4): 516-525 e515; quiz e543-e545. doi: 10.1016/j.cgh.2015.10.007.
[133] Wang J, Ma K, Han M, et al. Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: validation of the TPPM model[J]. Hepatol Int, 2014, 8(1): 64- 71. doi: 10.1007/s12072-013-9485-5.
[134] Ma K, Guo W, Han M, et al. Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: establishment of a novel logistical regression model[J]. Hepatol Int, 2012, 6(4): 735-743. doi: 10.1007/s12072- 012- 9344-9.
[135] Choudhury A, Kumar M, Sharma BC, et al. Systemic inflammatory response syndrome in acute-on-chronic liver failure: Relevance of ’golden window’: A prospective study[J]. J Gastroenterol Hepatol, 2017, 32(12): 1989-1997. doi: 10.1111/jgh.13799.
[136] Hernaez R, Sola E, Moreau R, et al. Acute-on-chronic liver failure: an update[J]. Gut, 2017, 66(3): 541-553. doi: 10.1136/ gutjnl-2016-312670.
[137] Bernsmeier C, Singanayagam A, Patel VC, et al. Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure[J]. Immunotherapy, 2015, 7(6): 641-654. doi: 10.2217/ imt.15.27.
[138] Wasmuth HE, Kunz D, Yagmur E, et al. Patients with acute on chronic liver failure display “sepsis-like” immune paralysis[J]. J Hepatol, 2005, 42(2): 195-201. doi: 10.1016/j.jhep.2004.10.019.

备注/Memo

备注/Memo:
[ 通信作者] 宁琴,E-mail: qning@vip.sina.com;王贵强,E-mail: john131212@sina.com
更新日期/Last Update: 2018-09-08